6-(benzenesulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-(benzenesulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine
• 化学式: C₁₈H₁₈N₂O₂S
• 分子量: 326.4
• InChiKey: GGGUCGXTROTHDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  84.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Arylsulphonyl substituted-tetrahydro- and hexahydro-carbazoles
  申请人：——

  公开号：US20030100596A1

  公开（公告）日：2003-05-29

  The invention provides compounds of formula I for use in treating conditions in which 5-HT 6 receptors are involved such as in anxiety, depression, schizophrenia, Alzheimer's disease, stress-related disease, panic, a phobia, obsessive compulsive disorder, obesity, post-traumatic stress syndrome, epilepsy, and other CNS disorders. 1

  该发明提供了公式I的化合物，用于治疗与5-HT6受体有关的疾病，如焦虑、抑郁症、精神分裂症、阿尔茨海默病、与压力相关的疾病、恐慌、恐惧症、强迫症、肥胖症、创伤后应激综合征、癫痫等中枢神经系统疾病。
• Arylsulphonyl substituted-tetrahydro-and hexahydro-carbazoles
  申请人：Pharmacia & Upjohn Company

  公开号：US20040162332A1

  公开（公告）日：2004-08-19

  The invention provides compounds of formula I for use in treating conditions in which 5-HT 6 receptors are involved such as in anxiety, depression, schizophrenia, Alzheimer's disease, stress-related disease, panic, a phobia, obsessive compulsive disorder, obesity, post-traumatic stress syndrome, epilepsy, and other CNS disorders. 1

  该发明提供了I式化合物，用于治疗与5-HT6受体有关的疾病，如焦虑、抑郁症、精神分裂症、阿尔茨海默病、与压力相关的疾病、惊恐、恐惧症、强迫症、肥胖症、创伤后应激综合症、癫痫和其他中枢神经系统疾病。1
• COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY
  申请人：Laboratorios Del. Dr. Esteve, S.A.

  公开号：EP2040755A1

  公开（公告）日：2009-04-01
• US6727274B2
  申请人：——

  公开号：US6727274B2

  公开（公告）日：2004-04-27
• [EN] COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY<br/>[FR] COMBINAISON D'UN INHIBITEUR DE LA CHOLINESTÉRASE ET D'UN COMPOSÉ AYANT UNE AFFINITÉ ENVERS LE RÉCEPTEUR 5-HT6
  申请人：ESTEVE LABOR DR

  公开号：WO2007147883A1

  公开（公告）日：2007-12-27

  [EN] The present invention relates to an active substance combination comprising at least one compound with 5-HT6 receptor affinity, and at least one cholinesterase inhibitor, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.
  [FR] La présente invention concerne une combinaison de substances actives comprenant au moins un composé ayant une affinité pour le récepteur 5-HT6 et au moins un inhibiteur de la cholinestérase. L'invention concerne également un médicament comprenant ladite combinaison de substances actives et l'utilisation de ladite combinaison lors de la fabrication d'un médicament.